397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment

April 16, 2026 · 50 min

About this episode

The episode discusses a breakthrough in pancreatic cancer treatment and advancements in off-the-shelf CAR-T therapy for lymphoma.

On this week’s episode of the Readout LOUD: a pancreatic cancer breakthrough and new hope for an off-the-shelf CAR-T treatment in lymphoma. Your favorite biotech podcasting crew is back to full strength this week, and we’re bringing you two newsy guest interviews. First, we’ll talk with Allogene Therapeutics Chief Medical Officer Zach Roberts about new study results that bolster the company’s efforts to develop an off-the-shelf CAR-T therapy for B-cell lymphoma, a type of blood cancer.Then, we’ll dive into the biggest news of the week: Revolution Medicines and the stunning survival benefit reported for its experimental drug in a Phase 3 pancreatic cancer study. Paul Oberstein, a pancreatic cancer expert from NYU Langone, will join us to discuss the Revolution Medicines data and what it means for pancreatic cancer patients.

People in this episode

Guests: Zach Roberts, Paul Oberstein

Topics covered

pancreatic cancer
CAR-T therapy
biotech news
blood cancer
clinical trials

Keywords

pancreatic cancer
CAR-T treatment
biotech podcast
clinical study
blood cancer
Allogene Therapeutics
Revolution Medicines

Mentioned in this episode

Organizations: Allogene Therapeutics, Revolution Medicines, NYU Langone

Places: B-cell lymphoma, pancreatic cancer